New Study From San Antonio Breast Cancer Symposium Proves Innovative Marker Makes It Easier for Physicians to Detect and Remove Cancer Than Ever Before Survey of 157 physicians finds Magseed® marker is more reliable, easy to use and improves logistics versus the traditional guidewire method.
San Antonio, TX
|
December 20, 2023 10:50 AM Eastern Standard Time
Research presented at the San Antonio Breast Cancer Symposium (SABCS) has found that surgeons and radiologists are moving away from one of the oldest traditional methods for locating and removing breast cancer, in favour of newer and more innovative technologies.
The seminal study found that since 2020, usage rates of the guidewire – the standard in breast cancer surgery for over 60 years - has fallen from 83% of physicians using the device, to just 18%.
In comparison, the rise of a unique metallic seed called the Magseed® marker has seen its adoption levels soar to 49%, meaning it has replaced the guidewire as the most used method for cancer localization.
Having gained FDA approval in 2015, the Magseed has helped over 250,000 patients worldwide to access minimally-invasive, wire-free breast cancer care. Gone are the days of a patient attending an early appointment to have a guidewire placed on the day of their surgery, and having to wait around the hospital until the time of operation.
Now, patients have the option of the Magseed being placed into the cancerous tissue any time ahead of surgery, at a time that suits them, safe in the knowledge it won’t move and can be easily found when the surgery takes place at a later date.
“This study demonstrates that the modern solutions to localization are providing such a vast improvement for patients and the physicians using them, that they have been able to be rapidly adopted across the hospital setting.” said Mr. James Harvey, Oncoplastic Breast Surgeon and author of the study presented at SABCS 2023.
The study from SABCS also surveyed each of the participating surgeons and radiologists, to understand the quality of user experience for each of their chosen devices for localizing tumors. Participants were asked about a range of topics including the reliability of locating the device, accuracy of cancer removal and the logistical benefits that the technology provides to the hospital.
Once again, the results showed a significant benefit in favour of the wire-free Magseed device. On average, radiologists gave the device 9/10 for overall satisfaction, while surgeons scored it 8/10. In comparison, the guidewire received 7/10 scores from both audiences.
“This is the first study to demonstrate that radiologists and surgeons now find Magseed to be more effective in patient care and a significant improvement on prior technologies.” continued Mr. Harvey.
It is also the first study to ascertain the advantages and disadvantages of each localization device against one another. The findings here could now have far-reaching implications for breast cancer treatment across the world.
The shift towards Magseed as the preferred localization device indicates there is growing interest in new technologies that improve patient outcomes. The landscape is changing for breast surgery, and it’s helping to drive ongoing research and innovation in cancer care.
-ENDS-
Notes to Editors:
- In the study, participants were asked to rate a range of features on a scale from 1-10 (10 being the highest level of satisfaction). Please find poster attached alongside this press release.
- This iBRA-NET satisfaction study includes findings from 84 breast units (65% of all UK sites), and was published at the San Antonio Breast Cancer Symposium on 7th December 2023.
- The Sentimag platform, along with Magseed marker and Magtrace lymphatic tracer, was developed by Endomag and is distributed by Mammotome in North America.
- More than 450,000 women have now received a better standard of breast cancer surgery with Endomag’s technologies.
- The Sentimag® is in use at over 1,000 hospitals in more than 45 countries across the world.
About Us
At Endomag, we believe everyone deserves a better standard of cancer care. That’s why we design our magnetic technologies with both the clinician and patient in mind. Many leading hospitals across the world use our unique solutions to help breast cancer patients avoid surgery when it isn’t needed, and experience better outcomes when it is.
At the heart of the company’s technologies is the Sentimag® localization system. The Sentimag® system features a probe which works like a metal detector. When it is placed near the skin’s surface, it can detect Endomag’s magnetic seed marker (Magseed®) and liquid tracer (Magtrace®), for accurate lesion localization and sentinel lymph node biopsy procedures.
Endomag’s technologies have already helped 450,000+ women worldwide to access more precise, and minimally invasive breast cancer treatment.
Contact Details
Endomag
Mary Nicholls
+44 1223 652540
